Tonix Pharmaceuticals Announces FDA-Aligned Plan for Phase 2 Lyme Study

What Happened
Tonix Pharmaceuticals Holding Corp. (TNXP) announced on August 3, 2026 that it received official minutes from an FDA Type C meeting confirming alignment on plans for an adaptive, randomized, placebo-controlled Phase 2 field study of TNX-4800 (a human anti-outer-surface protein A monoclonal antibody) to prevent Lyme disease in adults. The FDA-aligned design calls for a 3,300-participant study across Lyme-endemic U.S. areas with primary efficacy measured at six months after the first dose.

Key Details

• Study design: randomized 1:1 TNX-4800 450 mg subcutaneously vs. placebo, two-dose regimen (first dose early spring; second ~3 months later).
• Population & size: ~3,300 adults (18+) in Lyme-endemic U.S. areas who engage in activities increasing deer tick exposure.
• Endpoints & safety: primary efficacy endpoint—Lyme prevention at 6 months; key secondary—prevention at 3 months; primary safety objective—evaluate safety/tolerability for 52 weeks post-dosing.
• Timeline & logistics: majority of enrollment expected in the 2028 tick season (may extend to 2029 if attack rates are lower); investigational product manufacturing is on track for delivery to study sites in Q1 2027.

Why It Matters
This filing confirms regulatory alignment with the FDA on a pivotal Phase 2 field study approach and key trial parameters (size, endpoints, dosing), reducing near-term regulatory uncertainty for the TNX-4800 Lyme prevention program. For investors, the milestones to watch are delivery of investigational product in Q1 2027, enrollment progress in 2028 (or extension to 2029), and subsequent efficacy/safety readouts tied to the defined 3- and 6-month endpoints. The company also included standard forward-looking statements cautioning that timelines and outcomes may change.